Last updated: August 14, 2026

Application No. 18/578,932

NITROGEN-CONTAINING TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF

Final Rejection

Filed

Aug 22, 2024

Priority

Sep 01, 2021 — JP 2021-142742 +1 more

Examiner

KOSAR, ANDREW D

Art Unit

1625

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Shionogi & Co., Ltd.

OA Round

2 (Final)

This examiner grants 41% of cases after interview

— +31.8% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 263 resolved cases, 2023–2026

Examiner Intelligence

KOSAR, ANDREW D View full profile →

Grants 41% of resolved cases

Career Allowance Rate

109 granted / 263 resolved

-18.6% vs TC avg

Strong +32% interview lift

Without

With

+31.8%

Interview Lift

resolved cases with interview

Typical timeline

3y 5m

Avg Prosecution

16 currently pending

Career history

280

Total Applications

across all art units

Statute-Specific Performance

§101

3.5%

-36.5% vs TC avg

§103

27.1%

-12.9% vs TC avg

§102

20.3%

-19.7% vs TC avg

§112

30.5%

-9.5% vs TC avg

Black line = Tech Center average estimate • Based on career data from 263 resolved cases

Prosecution Timeline

Aug 22, 2024

Application Filed

Sep 24, 2025

Non-Final Rejection mailed

Mar 24, 2026

Response Filed

May 20, 2026

Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/555,233

Patent 12686671

NOVEL METHOD FOR PREPARING SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST

2y 9m to grant Granted Jul 21, 2026

18/504,859

Patent 12679820

COCRYSTALS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATMENT INVOLVING SAME

2y 8m to grant Granted Jul 14, 2026

17/626,029

Patent 12673951

SUBSTITUTED PYRAZOLOQUINAZOLINONE COMPOUNDS AND APPLICATION THEREOF

4y 5m to grant Granted Jul 07, 2026

17/925,854

Patent 12637480

HETEROCYCLIC COMPOUNDS AS STING MODULATORS

3y 6m to grant Granted May 26, 2026

18/673,671

Patent 12606773

IONIZABLE CATIONIC LIPIDS

1y 11m to grant Granted Apr 21, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4

Expected OA Rounds

41%

Grant Probability

73%

With Interview (+31.8%)

3y 5m (~1y 6m remaining)

Median Time to Grant

Moderate

PTA Risk

Based on 263 resolved cases by this examiner. Grant probability derived from career allowance rate.